Literature DB >> 15021775

Hearing changes after diagnosis in neurofibromatosis type 2.

Ann Masuda1, Laurel M Fisher, Mark L Oppenheimer, Zarina Iqbal, William H Slattery.   

Abstract

OBJECTIVE: Describe the changes in hearing ability and progression of disease over time in subjects with neurofibromatosis Type 2 enrolled in a multicenter natural history study of vestibular schwannomas in neurofibromatosis Type 2. STUDY
DESIGN: Retrospective clinical study.
SETTING: International neurofibromatosis Type 2 tertiary care centers. PATIENTS: Study participants had a clinical diagnosis of neurofibromatosis Type 2, at least one untreated vestibular schwannoma, and were at least 5 years old. Sixty-three subjects (108 ears) with audiology data at either short-term follow-up (7 mo-2 yr) or long-term follow-up (3-5 yr) after diagnosis were examined in this study. MAIN OUTCOME MEASURES: Changes in four-frequency pure-tone average and speech discrimination score before any treatment intervention for both follow-up intervals.
RESULTS: Within 2 years of the diagnosis of neurofibromatosis Type 2, 27% of the ears experienced a significant loss in pure-tone average relative to diagnosis, and 73% of the ears experienced no significant change in hearing.
CONCLUSION: Newly diagnosed neurofibromatosis Type 2 patients who do not require immediate treatment of both vestibular schwannomas are likely to have stable hearing in the unoperated ear(s) for approximately 1 to 2 years.

Entities:  

Mesh:

Year:  2004        PMID: 15021775     DOI: 10.1097/00129492-200403000-00012

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  15 in total

Review 1.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

Review 2.  News on the genetics, epidemiology, medical care and translational research of Schwannomas.

Authors:  C O Hanemann; D G Evans
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

3.  Options and strategies for hearing restoration in pediatric neurofibromatosis type 2.

Authors:  Hossein Mahboubi; William H Slattery; Gautam U Mehta; Gregory P Lekovic
Journal:  Childs Nerv Syst       Date:  2020-06-21       Impact factor: 1.475

4.  Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.

Authors:  Yingchao Zhao; Pinan Liu; Na Zhang; Jie Chen; Lukas D Landegger; Limeng Wu; Fu Zhao; Yanxia Zhao; Yanling Zhang; Jing Zhang; Takeshi Fujita; Anat Stemmer-Rachamimov; Gino B Ferraro; Hao Liu; Alona Muzikansky; Scott R Plotkin; Konstantina M Stankovic; Rakesh K Jain; Lei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-09       Impact factor: 11.205

5.  Progress of hearing loss in neurofibromatosis type 2: implications for future management.

Authors:  Georgios Kontorinis; Jaya Nichani; Simon R Freeman; Scott A Rutherford; Samantha Mills; Andrew T King; Deborah Mawman; Sue Huson; Martin O'Driscoll; D Gareth Evans; Simon K W Lloyd
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-08       Impact factor: 2.503

6.  Clinical outcome of neurofibromatosis type 2-related vestibular schwannoma: treatment strategies and challenges.

Authors:  Byung Sup Kim; Ho Jun Seol; Jung-Il Lee; Hyung Jin Shin; Kwan Park; Doo-Sik Kong; Do-Hyun Nam; Yang-Sun Cho
Journal:  Neurosurg Rev       Date:  2016-05-04       Impact factor: 3.042

Review 7.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

8.  Audiologic Natural History of Small Volume Cochleovestibular Schwannomas in Neurofibromatosis Type 2.

Authors:  Alvin T deTorres; Carmen C Brewer; Chris K Zalewski; Kelly A King; Robert Walker; Gretchen C Scott; Ashok R Asthagiri; Prashant Chittiboina; Hung Jeffrey Kim
Journal:  Otol Neurotol       Date:  2018-03       Impact factor: 2.311

9.  Hearing and facial function outcomes for neurofibromatosis 2 clinical trials.

Authors:  Scott R Plotkin; Simone L Ardern-Holmes; Fred G Barker; Jaishri O Blakeley; D Gareth Evans; Rosalie E Ferner; Tessa A Hadlock; Chris Halpin
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

10.  Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model.

Authors:  Xing Gao; Yingchao Zhao; Anat O Stemmer-Rachamimov; Hao Liu; Peigen Huang; ShanMin Chin; Martin K Selig; Scott R Plotkin; Rakesh K Jain; Lei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.